OPHTHOTECH CORP.
Profile
Company Names
OPHTHOTECH CORP.
Addresses
5 VAUGHN DRIVE, SUITE 106, PRINCETON, NJ 08540
ONE PENN PLAZA, 35TH FLOOR, NEW YORK, NY 10119
Phone Numbers
609-945-6050
212-845-8200
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
2007
State Incorporated:
DELAWARE
Total Amount Raised:
$46,066,565.00
Number of Funding Rounds:
7
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
7
2018-10-30
$11,399,894.00
$11,694,883.00
$294,989.00
Equity
6
2013-05-23
$16,666,668.00
$50,000,000.00
$33,333,332.00
Equity
5
2013-03-15
$1.00
$1.00
$0.00
4
2012-12-24
$1.00
$1.00
$0.00
3
2012-06-20
$1.00
$1.00
$0.00
2
2009-12-11
$15,000,000.00
$30,000,000.00
$15,000,000.00
Equity
1
2009-10-14
$3,000,000.00
$3,000,000.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
AXEL
BOLTE
DIRECTOR
DAVID
CARROLL
EXECUTIVE OFFICER
VIRTU INVESTMENTS MULTIFAMILY OPPORTUNITY FUND, LP
| FIVE OAKS INVESTMENT CORP.
| VIRTU INVESTMENTS MULTIFAMILY OPPORTUNITY FUND-III, LP
| OPHTHOTECH CORP.
| GREENACREAGE REAL ESTATE CORP.
| VIRTU EVERGREEN FUND, L.P.
| VIRTU QUALIFIED OPPORTUNITY FUND II, LP
| WHATSOEVER LLC
| VIRTU QUALIFIED OPPORTUNITY FUND III, LP
| VIRTU JOINT VENTURE OPPORTUNITY FUND, L.P.
THOMAS
DYRBERG
DIRECTOR
NICHOLAS
GALAKATOS
DIRECTOR
AFFYMAX INC
| PORTOLA PHARMACEUTICALS INC
| AVEO PHARMACEUTICALS INC
| TALIGEN THERAPEUTICS INC
| OPHTHOTECH CORP.
| NANOSTRING TECHNOLOGIES INC
| CATABASIS PHARMACEUTICALS INC
| CLARUS LIFESCIENCES III, L.P.
| CLARUS DEFINED EXIT I, L.P.
| CLARUS DE II, L.P.
| CLARUS IV-D, L.P.
| CLARUS IV-C, L.P.
| CLARUS IV-B, L.P.
| CLARUS IV-A, L.P.
| PRAXIS PRECISION MEDICINES, INC.
| BLACKSTONE LIFE SCIENCES YIELD NT (CYM) FEEDER L.L.C.
| BLACKSTONE LIFE SCIENCES YIELD L.P.
| BLACKSTONE LIFE SCIENCES YIELD T (CYM) FEEDER L.P.
| BLACKSTONE LIFE SCIENCES VI L.P.
| BLACKSTONE LIFE SCIENCES VI (LUX) SCSP
| BLACKSTONE LIFE SCIENCES VI - BL L.P.
| BLACKSTONE LIFE SCIENCES VI - B L.P.
LUTZ
GIEBEL
DIRECTOR
DAVID
GUYER
DIRECTOR, EXECUTIVE OFFICER
BRUCE
PEACOCK
EXECUTIVE OFFICER
MICHAEL
ROSS
DIRECTOR
CERVILENZ INC
| JUVARIS BIO THERAPEUTICS INC
| IKANO THERAPEUTICS INC.
| ADIMAB, INC.
| SV LIFE SCIENCES FUND V LP
| LINK MEDICINE CORP
| CATABASIS PHARMACEUTICALS INC
| SV LIFE SCIENCES FUND V STRATEGIC PARTNERS, L.P.
| ARSANIS, INC.
| BALANCE HEALTH CORP
| ABCAM PLC
| ADIMAB, LLC
| AVITIDE, INC.
| OPHTHOTECH CORP.
| THESAN PHARMACEUTICALS, INC.
| SV LIFE SCIENCES FUND VI, L.P.
| DECIPHERA PHARMACEUTICALS, LLC
| DEMENTIA DISCOVERY LP
| AMERICLEAN HOLDINGS LLC
| SV LIFE SCIENCES FUND VI STRATEGIC PARTNERS, L.P.
| FRESCO FOODS, INC.
| SUTRO BIOPHARMA INC
| RIBOMETRIX, INC.
| JASON RYAN
| NICE RECOVERY SYSTEMS LLC
| THERINI BIO, INC.
| MAINE CRISP COMPANY, LLC
| JOSEPH VENTURES ALLIUM I LLC, SERIES A
| XILIO THERAPEUTICS, INC.
| JOSEPH VENTURES ALLIUM I LLC, SERIES C
| SV LIFE SCIENCES FUND IV CF, L.P.
| ANDOVIA INC.
| TREX HOLDINGS INC.
| DUALITAS THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY
PHARMACEUTICAL PREPARATIONS [2834]
DECLINE TO DISCLOSE
Equity
2018-10-30
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#

